Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07469202 (Prospective, Multi Center, Open Label Non Inferiority Trial Evaluating the Clinical Adequacy of Intraoperative Tumor Fluorescence With Cytalux™), which is not on this map. Cited by 101 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Multi Center, Open Label Non Inferiority Trial Evaluating the Clinical Adequacy of Intraoperative Tumor Fluorescence With Cytalux™ (Pafolacianine) Across Two Preoperative Administration Windows in Adults Undergoing Surgery for Suspected Lung Cancer or Confirmed Ovarian Cancer
Who cites it
101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Application of fluorescent tracers in ovarian cancer surgical navigation: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Fluorescence imaging for real-time detection of breast cancer tumors using IV injection of indocyanine green with non-conventional imaging: a systematic review of preclinical and clinical studies of perioperative imaging technologies.Breast cancer research and treatment · 2024Pooled it
- Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Intraoperative Molecular Imaging With Pafolacianine in Resection of Occult Pulmonary Malignancy in the ELUCIDATE Trial.The Annals of thoracic surgery · 2025Trial
- Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.Annals of surgical oncology · 2024Trial
- A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer.Science advances · 2026Article
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Progress in the Design and Clinical Application of Probes for Fluorescence-Guided Laparoscopic Surgery.Chemical & biomedical imaging · 2026Review
- Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery.Journal of clinical medicine · 2026Review
- Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression.Research square · 2026Article
- Translation of Intraoperative Molecular Imaging for Clinical Use.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Erasable FAP Targeted Spray-On Probe for Fluorescence-Guided Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics · 2026Review
- Translational development of an SGLT2-targeted near-infrared contrast agent for intraoperative imaging of early-stage lung cancer.EJNMMI research · 2026Article
- Advanced imaging techniques for tumor intraoperative navigation imaging.Npj imaging · 2026Review
- IFITM1-targeted NIR-II fluorescence imaging enables visualisation of colorectal cancer and metastatic lymph nodes.Journal of translational medicine · 2026Article
- Fluorescence Discrimination of Cancer from Inflammation by Selective Targeting Folate Receptor α.Chemical & biomedical imaging · 2026Article
- In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag-Dyes.Research square · 2026Article
- E-Cadherin Is an Accurate Target for Fluorescence-Guided Imaging of Lymph Nodes.Current issues in molecular biology · 2026Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 11 institutions in 2 countries.
Funding
Abstract
purposeThe adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors. This confirmatory study examined the use of pafolacianine for real-time detection of folate receptor-positive ovarian cancer.
methodsThis phase III, open-label, 11-center study included subjects with known or suspected ovarian cancer, scheduled to undergo cytoreductive surgery. The objectives were to confirm safety and efficacy of pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging to detect macroscopic lesions not detected by palpation and normal white light.
resultsFrom March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor-positive ovarian cancer comprised the full analysis set for efficacy. In 33.0% of patients (95% CI, 24.3 to 42.7;
conclusionThis phase III study of pafolacianine met its primary efficacy end point, identifying additional cancers not otherwise identified or planned for resection. Pafolacianine may offer an important real-time adjunct to current surgical approaches for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.